Barclays
SPRB icon

Barclays’s Spruce Biosciences SPRB Stock Holding History

Barclays’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$55.9K Buy
1,150
+476
+71% +$24.1K ﹤0.01% 4535
2026
Q2 		$36.4K Buy
+674
New +$37.7K ﹤0.01% 4426
2023
Q2 		– Sell
-100
Closed -$16.5K – 5171
2023
Q1 		$16.5K Sell
100
-2
-2% -$371 ﹤0.01% 4686
2022
Q4 		$8.38K Sell
102
-51
-33% -$4.27K ﹤0.01% 4944
2022
Q3 		$15K Hold
153
– – ﹤0.01% 4171
2022
Q2 		$20K Sell
153
-16
-9% -$2.05K ﹤0.01% 4415
2022
Q1 		$25K Buy
+169
New +$31.4K ﹤0.01% 4381

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Pinnacle Wealth Planning Services
Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return

Barclays's SPRB Position: Q3 2026 in Review

Barclays increased its Spruce Biosciences (SPRB) stake by 71% in Q3 2026, buying an estimated $24.1K and bringing the position to 1,150 shares worth $55.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4535.

Barclays first reported a position in SPRB in Q1 2022 and has held it in 7 quarters since. 19 funds tracked by Wall St. Rank hold SPRB as of Q3 2026.

  • Barclays held 1,150 shares of Spruce Biosciences worth $55.9K as of Q3 2026.
  • Barclays bought 476 Spruce Biosciences shares in Q3 2026, an estimated $24.1K.
  • Spruce Biosciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4535 holding.
  • Barclays first reported a position in Spruce Biosciences in Q1 2022 and has held it in 7 quarters since.
  • 19 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.